Home | Welcome to Contract Pharma   
Last Updated Friday, August 1 2014
Print RSS Feed

Search Results for 'Gil Y. Roth'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Top 20 Pharma Report
Published July 16, 2013
Our annual look at the 20 biggest players in the Pharmaceutical marketplace Read More »
Top 10 Biopharma Companies
By Gil Y. Roth, Editor
Published July 18, 2012
Our annual look at the 10 biggest players in the Biopharmaceutical marketplace Read More »
The Top 20 Pharmaceutical Companies
By Gil Y. Roth
Published July 14, 2011
Our annual look at the biggest companies in the pharma industry Read More »
Newsmakers: Nancy Lurker
By Gil Roth, Editor
Published March 7, 2014
A CSO adapts for a new era in healthcare. Read More »
Generic Manufacturing: GDUFA & CMOs
By Gil Y. Roth, Contract Pharma
Published March 6, 2013
Generic facility fees cause sticker shock Read More »
2010 Top 20 Pharma Companies
Published July 19, 2012
Slowing sales, mega-mergers, generic implosions and whipsawing exchange rates have caused some shakeups within the Top 20 Pharma ranks. The loss of Wyeth and Schering-Plough, coupled with Roche’s defection to the Biopharma list, led us to find… Read More »
Newsmakers: James L. Botkin
By Gil Y. Roth, Contract Pharma
Published May 30, 2012
Alkermes’ James L. Botkin Read More »
By Gil Y. Roth
Published November 14, 2011
Euro long way from the governor’s mansion . . . Read More »
2008 Top 10 Biopharmaceutical Companies Report
Published July 18, 2008
After years of producing this report, I’ve finally settled on definitive criteria for the Top Biopharma ranks! After consulting with Ronald A. Rader, president of the Biotechnology Information Institute, I decided that a Top Biopharma company is one that makes more than 40% of its drug revenues by selling biologic products, including biotherapeutics, vaccines and other proteins. Read More »
2006 Top 20 Pharmaceutical Companies Report
Published July 18, 2006
Last year (our 2005 edition), Pfizer was 47% ahead of its closest competitor in drug revenues ($46 billion to $31 billion), but that margin was shaved to 30% in 2005 as Pfizer sales dropped 4%. Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On